Literature DB >> 4058075

Sequential methotrexate (MTX) and 5-fluorouracil (FU) in human tumor xenografts.

K Wayss, R Herrmann, J Mattern, M Volm.   

Abstract

Human and animal tumor-lines heterotransplanted in nude mice were treated with MTX and FU sequentially. In order to investigate the relationship between tumor response and drug toxicity sequence, time and dose of both MTX and FU were varied. Pretreatment with MTX followed by FU with intervals of 3 or 24 h produced superior therapeutic results when compared to single administration of MTX or FU, simultaneous treatment, or the reverse sequence. In the MTX followed by FU regimen, dose reduction of either MTX or FU tended to decrease the anti-tumor effect. To investigate the toxic effects of different regimens, tumor-free nude mice were treated with MTX and FU the same way as the tumor-bearing animals. In this case, toxicity (weight loss, leukopenia) was more pronounced in those schedules with the best therapeutic results. However, toxicity appears to be more clearly related to the applied FU-dose.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4058075     DOI: 10.1007/BF02934777

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  21 in total

1.  Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil.

Authors:  J R Bertino; W L Sawicki; C A Lindquist; V S Gupta
Journal:  Cancer Res       Date:  1977-01       Impact factor: 12.701

2.  5-Fluorouracil and methotrexate combination chemotherapy: the effect of drug scheduling.

Authors:  J H Mulder; T Smink; L M van Putten
Journal:  Eur J Cancer Clin Oncol       Date:  1981-07

3.  Effectiveness of intermediate-dose methotrexate and high-dose 5-fluorouracil as sequential combination chemotherapy in refractory breast cancer and as primary therapy in metastatic adenocarcinoma of the colon.

Authors:  G Tisman; S J Wu
Journal:  Cancer Treat Rep       Date:  1980 Aug-Sep

4.  Therapeutic response of human lung tumour xenografts to cyclophosphamide.

Authors:  J Mattern; S Jaeger; K Wayss; M Volm
Journal:  Anticancer Res       Date:  1982 Nov-Dec       Impact factor: 2.480

5.  Sequential methotrexate and 5-FU in the treatment of colorectal cancer.

Authors:  B Weinerman; B Schacter; H Schipper; D Bowman; M Levitt
Journal:  Cancer Treat Rep       Date:  1982-07

6.  Sequential methotrexate-5-fluorouracil treatment of squamous cell carcinoma of the head and neck.

Authors:  U Ringborg; G Ewert; J Kinnman; P G Lundqvist; H Strander
Journal:  Cancer       Date:  1983-09-15       Impact factor: 6.860

7.  Optimal schedule of methotrexate and 5-fluorouracil in human breast cancer.

Authors:  C Benz; T Tillis; E Tattelman; E Cadman
Journal:  Cancer Res       Date:  1982-05       Impact factor: 12.701

8.  Sequential methotrexate and 5-FU in breast cancer resistant to the conventional application of these drugs.

Authors:  R Herrmann; C Manegold; M Schroeder; F J Tigges; H Bartsch; F Jungi; D Fritze
Journal:  Cancer Treat Rep       Date:  1984-10

9.  Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism.

Authors:  E Cadman; R Heimer; L Davis
Journal:  Science       Date:  1979-09-14       Impact factor: 47.728

10.  Preliminary report on the efficacy of sequential methotrexate and 5-fluorouracil in advanced breast cancer.

Authors:  A M Gewirtz; E Cadman
Journal:  Cancer       Date:  1981-06-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.